162 related articles for article (PubMed ID: 37400683)
1. Healthcare Resource Use and Costs Associated with Organ Damage in Newly Diagnosed Adults with Systemic Lupus Erythematosus in the UK.
Stirnadel-Farrant HA; Golam SM; Naisbett-Groet B; Gibson D; Langham J; Langham S; Samnaliev M
Rheumatol Ther; 2023 Oct; 10(5):1183-1197. PubMed ID: 37400683
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
Bell CF; Ajmera MR; Meyers J
Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
[TBL] [Abstract][Full Text] [Related]
3. Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid use Among Adults with Systemic Lupus Erythematosus in the UK.
Stirnadel-Farrant HA; Golam SM; Naisbett-Groet B; Gibson D; Langham J; Langham S; Samnaliev M
Rheumatol Ther; 2023 Oct; 10(5):1167-1182. PubMed ID: 37400682
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization and costs in patients with a newly confirmed diagnosis of lupus nephritis in the United States over a 5-year follow-up period.
Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM
BMC Health Serv Res; 2024 May; 24(1):691. PubMed ID: 38822336
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany.
Schultze M; Garal-Pantaler E; Pignot M; Levy RA; Carnarius H; Schneider M; Gairy K
BMC Rheumatol; 2024 May; 8(1):18. PubMed ID: 38755673
[TBL] [Abstract][Full Text] [Related]
6. Healthcare Resource Utilization and Associated Costs in Patients With Systemic Lupus Erythematosus Diagnosed With Lupus Nephritis.
Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM; Von Feldt J
Cureus; 2023 Apr; 15(4):e37839. PubMed ID: 37214060
[TBL] [Abstract][Full Text] [Related]
7. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.
He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C
Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Economic Burden of Systemic Lupus Erythematosus in the Years Preceding End-Stage Kidney Disease Diagnosis: A Retrospective Observational Study.
Huang SP; Guisinger A; Averell C; Bell CF; Rubin B
Rheumatol Ther; 2023 Jun; 10(3):551-562. PubMed ID: 36738424
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
Lokhandwala T; Coutinho AD; Bell CF
Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
[TBL] [Abstract][Full Text] [Related]
10. Hospital Healthcare Resource Utilization and Associated Hospital Costs of Patients With Lupus Nephritis in China: A National Administrative Claim Database Study.
He X; Zhu X; Tang Z; Gairy K; Juliao P; Wu Z; Han S
Value Health Reg Issues; 2024 Jun; 43():101001. PubMed ID: 38850589
[TBL] [Abstract][Full Text] [Related]
11. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
12. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.
Jiang M; Near AM; Desta B; Wang X; Hammond ER
Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733
[TBL] [Abstract][Full Text] [Related]
13. Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: A general population-based study.
McCormick N; Marra CA; Sadatsafavi M; Aviña-Zubieta JA
Lupus; 2018 Jul; 27(8):1247-1258. PubMed ID: 29665755
[TBL] [Abstract][Full Text] [Related]
14. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States.
Bell CF; Huang SP; Cyhaniuk A; Averell CM
Lupus; 2023 Feb; 32(2):301-309. PubMed ID: 36542670
[TBL] [Abstract][Full Text] [Related]
15. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts.
Jönsen A; Hjalte F; Willim M; Carlsson KS; Sjöwall C; Svenungsson E; Leonard D; Bengtsson C; Rantapää-Dahlqvist S; Pettersson S; Gunnarsson I; Zickert A; Gustafsson JT; Rönnblom L; Petersson IF; Bengtsson AA; Nived O
Semin Arthritis Rheum; 2016 Jun; 45(6):684-90. PubMed ID: 26743074
[TBL] [Abstract][Full Text] [Related]
16. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
17. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
18. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
[TBL] [Abstract][Full Text] [Related]
19. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization.
Schwarting A; Friedel H; Garal-Pantaler E; Pignot M; Wang X; Nab H; Desta B; Hammond ER
Rheumatol Ther; 2021 Mar; 8(1):375-393. PubMed ID: 33544369
[TBL] [Abstract][Full Text] [Related]
20. Healthcare utilization and costs of systemic lupus erythematosus in Medicaid.
Kan HJ; Song X; Johnson BH; Bechtel B; O'Sullivan D; Molta CT
Biomed Res Int; 2013; 2013():808391. PubMed ID: 23484162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
